Recently, mixed treatment comparisons (MTC) have been presented as an extension of traditional meta-analysis by including multiple different pairwise comparisons across a range of different interventions. MTC allow for indirect comparisons and can therefore provide very useful information for clinical and reimbursement decision-making in the absence of head-to-head data. In this article, we provide an introductory overview of MTC illustrated with example analyses of different drug treatments in rheumatoid arthritis using a continuous patient-reported end point. As a background, we start with an overview of the traditional meta-analyses for pairwise trials, and the difference between a traditional approach and a Bayesian approach. Next, the Bayesian MTC for continuous outcomes are presented. We finish with a discussion of how MTC can best be presented in order to maximize acceptance by target audiences, i.e., clinicians and market access decision-makers. © 2008, International Society for Pharmacoeconomics and Outcomes Research (ISPOR).
CITATION STYLE
Jansen, J. P., Crawford, B., Bergman, G., & Stam, W. (2008). Bayesian meta-analysis of multiple treatment comparisons: An introduction to mixed treatment comparisons. Value in Health, 11(5), 956–964. https://doi.org/10.1111/j.1524-4733.2008.00347.x
Mendeley helps you to discover research relevant for your work.